10/02/2025 Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:
- adults 60 years of age or older; and
- adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
Funding status
RRecombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.
RThe recombinant varicella zoster virus glycoprotein E injection should be used in line with the additional clinical criteria listed in the Annex.